What should be done for patients with liver lesions in the LI-RADS 2 and 3 categories? (original) (raw)

Liver cancer, primarily hepatocellular carcinoma (HCC), poses significant global health challenges, especially in cirrhotic patients. Current diagnostic methods, including LI-RADS, provide a framework for categorizing liver lesions but face limitations, particularly in LI-RADS 2 and 3 categories. This paper discusses the management of LI-RADS 2 lesions, suggesting that raising alpha-fetoprotein levels may warrant biopsy consideration despite its limitations in diagnosing HCC. It recommends a more cautious approach in interpreting LI-RADS 2 lesions, advocating for additional MRI examinations to better differentiate between benign and malignant nodules.